posted on 2016-09-27, 00:00authored byIan M. Robertson, Sandra E. Pineda-Sanabria, Ziqian Yan, Thomas Kampourakis, Yin-Biao Sun, Brian D. Sykes, Malcolm Irving
The binding of Ca2+ to cardiac troponin C (cTnC) triggers
contraction in heart muscle. In the diseased heart, the myocardium
is often desensitized to Ca2+, which leads to impaired
contractility. Therefore, compounds that sensitize cardiac muscle
to Ca2+ (Ca2+-sensitizers) have therapeutic
promise. The only Ca2+-sensitizer used regularly in clinical
settings is levosimendan. While the primary target of levosimendan
is thought to be cTnC, the molecular details of this interaction are
not well understood. In this study, we used mass spectrometry, computational
chemistry, and nuclear magnetic resonance spectroscopy to demonstrate
that levosimendan reacts specifically with cysteine 84 of cTnC to
form a reversible thioimidate bond. We also showed that levosimendan
only reacts with the active, Ca2+-bound conformation of
cTnC. Finally, we propose a structural model of levosimendan bound
to cTnC, which suggests that the Ca2+-sensitizing function
of levosimendan is due to stabilization of the Ca2+-bound
conformation of cTnC.